NCT00865891View on ClinicalTrials.gov

A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

July 31, 2005

Study Completion Date

July 31, 2005

Conditions
Healthy
Interventions
DRUG

Nifedipine Extended Release tablets 60 mg, single dose

A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions

DRUG

ADALAT® CC Extended Release Tablets 60 mg

B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865891 - A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter